Literature DB >> 1282181

Pharmacological characterization of nicorandil by 86Rb efflux and isometric vasorelaxation studies in vascular smooth muscle.

V A Kreye1, T Lenz, D Pfründer, U Theiss.   

Abstract

Nicorandil and cromakalim were found to stimulate 86Rb efflux (a marker of K+ ions) from resting preparations of rabbit aorta. This action was suppressed by 10(-5) M glibenclamide, an antagonist of K(+)-channel openers in vascular smooth muscle. Through intracellular production of cyclic GMP, and subsequent suppression of cellular Ca2+ activation, nitrovasodilators interfere indirectly with the activation of Ca(2+)-dependent ion channels. 8-Bromo-cyclic GMP and sodium nitroprusside antagonized the Ca(2+)-dependent 86Rb efflux induced by 3 x 10(-7) M norepinephrine. When nicorandil and cromakalim were investigated in the same experimental setup in the presence of glibenclamide to suppress stimulation of K+ channels, only nicorandil also suppressed the norepinephrine-induced increase of the 86Rb efflux. These results confirm that nicorandil acts as both an opener of K+ channels and a nitrovasodilator. Nicorandil relaxed helical strips from rabbit aorta contracted by 10(-7) M norepinephrine, but in contrast to the relaxant action of cromakalim, this response was not antagonized by the use of glibenclamide, indicating a greater importance of the nitrovasodilator mechanism than of the K(+)-channel-opening activity for relaxation in this tissue. However, when the nitrate-like action of nicorandil was suppressed by 10(-5) M methylene blue, the K(+)-channel-opening activity was unmasked on addition of 10(-4) M glibenclamide at high concentrations of nicorandil.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282181     DOI: 10.1097/00005344-199206203-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Effects of the K+ channel blocker tedisamil on 86Rb efflux induced by cromakalim, high potassium and noradrenaline, and on mechanical tension in rabbit isolated vascular smooth muscle.

Authors:  V A Kreye; D Pfründer; U Theiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

Review 2.  Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.

Authors:  C Knight; H Purcell; K Fox
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

Review 3.  Management of vasospastic angina--role of nicorandil.

Authors:  J C Kaski
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

4.  Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure.

Authors:  Satofumi Iida; Haruki Kinoshita; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

5.  Effects of chronic treatment with a low dose of nicorandil on the function of the rat aorta during ageing.

Authors:  Stéphanie Raveaud; Paulette Mezin; Nicole Lavanchy; Barry Starcher; Robert P Mecham; Jean Verdetti; Gilles Faury
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-03-26       Impact factor: 2.557

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.